Author, Entrpreneur & Community Servant Dr. Clay Siegall


Have you ever heard of a guy named Clay Siegall? Are you interested in the field of cancer research? Have you ever heard of a company that’s known as Seattle Genetics? Well, all three of these questions have a connection because all three are tied to the same subject. Clay Siegall, Ph.D.,is the head man in charge at Seattle Genetics. This company specializes in developing targeted-cancer therapies, and it commercializes the therapies for greater use. Dr. Siegall has been involved with many of the industries top organizations. These organizations just so happens to be the National Cancer Institute, the National Institute of Health and Bristol-Myers Squibb. Siegall is from the old school in a sense, but he uses new-age technology to fight cancer.

Siegall has many different titles because he has a diverse educational background. Many people know him to be a scientist, a doctor, a businessman and a civil servant. Seattle Genetics was founded back in 1998, but no one really new if it would make an impact on society. Siegall has been dedicated from day one because this deadly illness has reached home. While in college, his father became stricken with cancer. The aggressive treatments during that particular time was hard to witness. Amputations and radical surgeries were the norm, but Siegall knew that there had to be a better way. After the passing of his father, Siegall’s mind was set on becoming a force in cancer research. He ended-up attaining a B.S. in Zoology as well as attaining a Ph.D in Genetics. Respectively, these high-level degrees came from the affluent George Washington University and from the University of Maryland.

As of present day, Seattle Genetics has become a major force in cancer research. The company’s top medication, ADCETRIS, has generated hundreds of millions of dollars and Siegall himself has won numerous awards in the process. The guy has literally written up to 70 publications that pertains to this subject, and he holds at least 15 patents. Brighter days are upon us all and Dr. Clay Siegall is doing his absolute best to keep it this way.

Eric Lefkofsky is on a Mission to Bring Cancer under Control by Data-Enabled Precision Medicine


Eric Lefkofsky, the CEO and co-founder of Tempus, is on a mission to bring efficient cancer treatment solutions through data-enabled precision medicine system. It should be noted that almost 40 percent of American adults are experiencing cancer diagnosis during their life time. Also a significant increase in the number of patients expected from the current 14.5 million to 19 million by 2024. However, Lefkofsky and his Tempus ensure that future would not be as bad as the numbers considering his efforts for data-enabled precision medicine. Previously, his personal experience shocked him that there was no data collection and streamlined analysis on cancer treatments and its response information with respect to molecular data of the patients. Lefkofsky learned that if he could ensure data collection based on digital technology that would save millions of cancer patients. That is where Tempus was born and read full article.

 

The firm is on a mission to change the way cancer care is provided. It has developed a platform that analyzes patients’ molecular and clinical data. It faced few initial hurdles including expensive analytical software and inefficient information storage system considering most physicians go for progress notes. To overcome this, Lefkofsky led Tempus to develop a software with optical character recognition and natural language processing options. In the end, the text fields with pertinent notes transform to structured data for using it in advanced cancer treatment. While coming to molecular data, it is captured through human genome sequencing. With the data captured by Tempus, the physicians can refer the historical cancer treatments, its effectiveness with respect to molecular data, and go for more accurate and effective treatment methods and learn more about Eric.

 

Eric Lefkofsky is also the Chairman and co-founder of Groupon and co-founder of a number of firms including Mediaocean, InnerWorkings, Echo Global Logistics, Lightbank, and Uptake. He is also known for various philanthropic initiatives and founded Lefkofsky Foundation to support educational, scientific, and charitable organizations around the world.

 

Lefkofsky completed his graduation from the University of Michigan and secured his J.D. from the Law School of the same university. He is serving on the boards of Children’s Memorial Hospital located in Chicago and the Chicago Art Institute.

How Eric Lefkofsky is Approaching Healthcare Data with ‘Tempus’


The team at the new tech start up Tempus are focused on life changing innovations within the medical research field. Tempus was co founded by Eric Lefkofsky who is most well known for his work on his other company, Groupon. Lefkofsky was drawn to creating Tempus after his wife was diagnosed with breast cancer. During her trying times, and many visits to the hospital, Lefkofsky saw how impossibly complicated sending and receiving data records was. Patient data is the lifeblood of innovation for medicine and when doctors can’t access that data, people suffer.

The core concept surrounding Tempus is to take existing digital medical records, or EMRs, and push them through a data aggregate database. There the information will be verified, sourced, and sent into another pool that can be used by doctors, patients, and other medical professionals around the world. The need for access to this data cannot be understated and Lefkofsky used his own experiences to inform Lefkofsky work at Tempus.

Lefkofsky spoke at at the Fortune Brainstorm Health conference, located in San Diego this past May, in order to highlight the importance of his work with Tempus. Lefkofsky pointed to data as the primary focus of his speech, “You need therapeutic and outcome response data.” Medical research is incredibly tough to parse and that is why a surplus of information and accessibility is a primary concern. Look at a drug like Herceptin and consider that it is effective in X amount of patients. Why does it not work for the other patients? Aggregated data can help answer these tough questions.

Eric Lefkofsky has a long history of successful work in the tech industry. He co-founded Tempus and worked hard to bring Groupon to life. Leftkofsky also has a fascinating history of work within Chicago. Lefkofsky is a Chairman for the prestigious Steppenwolf Theatre Company as well as an adjunct professor at the University of Chicago. Lefkofsky also makes sure to give back through his charitable group, the Lefkofsky Family Foundation. Lefkofsky’s foundation services communities with initiatives that aim to enhance their lives and improve the area that they live in.

for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/